Prostatype Genomics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Prostatype Genomics
Access all reports
Prostatype Genomics AB specializes in developing, manufacturing, and marketing the Prostatype genetic test, which assesses the aggressiveness of prostate cancer. The test aids clinicians and patients in making informed treatment decisions by minimizing both over- and under-treatment, thereby improving patient quality of life and optimizing healthcare resources. The Prostatype test uses genetic expression data from prostate biopsies combined with clinical parameters to predict cancer prognosis. The company is headquartered in Solna, Sweden, and its shares are listed on the Nasdaq Stockholm.
Latest articles
The Art of Portfolio Management: Lessons from Tom O'Hara
Tom O'Hara shares insights on stock picking, navigating market distractions, and the importance of one-on-one meetings with management teams.
4 Oct 2024
The Samsung Co-CEOs: Jong-Hee Han & Young-Hyun Jun
Samsung Electronics' dual-CEO structure, led by Jong-Hee Han and Young-Hyun Jun, is designed to navigate the complexities of its diverse business.
3 Oct 2024
Irwin Jacobs & Andrew Viterbi: Qualcomm's Pioneering Founders
In 1985, Irwin Jacobs and Andrew Viterbi co-founded Qualcomm, a leading company in telecommunications and semiconductor innovation.
3 Oct 2024
Ticker symbol
PROGEN
Country
🇸🇪 Sweden